Professor and Associate Director
Indiana University School of Medicine
Indianapolis, Indiana
Dr. Mark Kelley, Professor of Pediatrics and Associate Director of Basic Science at the Indiana University Simon Comprehensive Cancer Center (IUSCCC). Dr. Kelley's studies have focused on the enzyme apurinic/apyrimidinic endonuclease 1/ Redox effector factor-1 (APE1/Ref-1)—mechanistically as well as a therapeutic target in cancers and other diseases such as IBD and DR. His original work led to the formation of Apexian Pharmaceuticals as CSO and co-founder targeting Ref-1 to produce new therapeutics for some of the deadliest and hardest-to-treat cancers, as well as other indications. Kelley co-directs the Cancer Drug Discovery and Development Accelerator programme in the IUSCCC, and is co-PI of a NCI T32 Pediatric and Adult Translational Cancer Drug Discovery and Development Training Program grant. As well as the above, he is the Chair of the IU Conflict of Interest Committee, and is a consultant to Ocuphire Pharma. His honours include AAAS Science Fellow, Glen W Irwin Jr., MD Research Scholar, Bantz-Petrino Translating Research into Practice Scholar and Irwin Research Scholar. He has been continuously funded by NIH/NCI for over 30 years. All of his career discoveries have culminated in 19 patents and over 203 articles in peer reviewed journals as well as 36 review articles/book chapters.
Disclosure information not submitted.
Monday, October 21, 2024
2:30 PM – 3:30 PM MT